Possible downside from here

Looks like there is bad news from novavax, that being that their vaccine isn't effecrive against new strains of virus.
Looks to me that post market has imthe asset pumped up on the cheap in postmarket conditions ripe to be shorted at the open.
Price at end of post market being $170
Beyond Technical AnalysisFundamental AnalysisTechnical Indicators

Clause de non-responsabilité